glp 1 agonista Schematic illustration of monoagonists, dual agonists and triple El desarrollo de los agonistas

A class-action lawsuit filed against CVS Caremark argues that the PBM dropping coverage of Zepbound for Wegovy is illegal

With Transform Diabetes Care, Aetna gives employers and their employees the tools, education and support to stick with diabetes treatment and manage their condition with success

semaglutide, n=21), weight and BMI were 90.5 kg (83.4, 107.9) and 34.0 kg/m2 (31.7, 38.7), respectively, with a post-bariatric weight regain of 15.1% (10.6, 22.8) of total body weight and 4.6 kg/m2 (3.3, 6.2)

Miami's Most Trusted Health Insurance Agency

Made for all of you

The focus of the Indian pharmaceutical market is increasingly shifting to biologics, including peptides, biosimilars, and GLP-1-based therapies